📊 BCLI Key Takeaways
Investment Thesis
Brainstorm Cell Therapeutics faces severe financial distress with negative stockholders' equity of -7.7M, liabilities exceeding assets by 7.7x, and no revenue generation. The company is burning cash at an unsustainable rate (-6.2M operating cash flow) with minimal liquidity (5.0K cash) and a critically low current ratio of 0.06x, indicating imminent solvency concerns.
BCLI Strengths
- Company has not yet filed for bankruptcy, indicating some ongoing operations
- EPS improved 61.5% year-over-year, though still deeply negative
- No long-term debt obligations that could accelerate financial distress
BCLI Risks
- Negative stockholders' equity (-7.7M) indicates liabilities exceed assets; company is technically insolvent
- Zero revenue with -7.9M net loss and -6.2M operating cash burn; business model not generating income
- Critical liquidity crisis: only 5.0K cash on hand with 9.1M total liabilities and current ratio of 0.06x
- Negative ROA of -570.5% demonstrates severe asset inefficiency and value destruction
- No insider buying activity in last 90 days suggests lack of management confidence
- Dependency on external financing or capital raises for survival
Key Metrics to Watch
- Cash balance and runway to next financing event
- Quarterly cash burn rate trends and path to profitability/revenue generation
- Changes in stockholders' equity and potential debt restructuring or dilutive equity raises
- Operating cash flow improvements or further deterioration
BCLI Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
BCLI Profitability Ratios
BCLI vs Healthcare Sector
How BRAINSTORM CELL THERAPEUTICS INC. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
BCLI Balance Sheet & Liquidity
BCLI 5-Year Financial Trend
5-Year Trend Summary: BRAINSTORM CELL THERAPEUTICS INC.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-6.00 indicates the company is currently unprofitable.
BCLI Growth Metrics (YoY)
BCLI Capital Allocation
BCLI SEC Filings
Access official SEC EDGAR filings for BRAINSTORM CELL THERAPEUTICS INC. (CIK: 0001137883)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BCLI
What is the AI rating for BCLI?
BRAINSTORM CELL THERAPEUTICS INC. (BCLI) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are BCLI's key strengths?
Company has not yet filed for bankruptcy, indicating some ongoing operations. EPS improved 61.5% year-over-year, though still deeply negative.
What are the risks of investing in BCLI?
Negative stockholders' equity (-7.7M) indicates liabilities exceed assets; company is technically insolvent. Zero revenue with -7.9M net loss and -6.2M operating cash burn; business model not generating income.
What is BCLI's revenue and growth?
BRAINSTORM CELL THERAPEUTICS INC. reported revenue of N/A.
Does BCLI pay dividends?
BRAINSTORM CELL THERAPEUTICS INC. does not currently pay dividends.
Where can I find BCLI SEC filings?
Official SEC filings for BRAINSTORM CELL THERAPEUTICS INC. (CIK: 0001137883) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BCLI's EPS?
BRAINSTORM CELL THERAPEUTICS INC. has a diluted EPS of $-0.91.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.